About

Publications While At HealthPartners

selected publications

Journal Article

Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. 

Cardiovascular Diabetology. 2022

Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial. 

Diabetes care. 2016

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. 

Diabetic Medicine. 2011

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. 

Lancet (London, England). 2010

Review

Once-weekly insulin efsitora alfa: design and rationale for the QWINT phase 3 clinical development programme [review]. 

Diabetes, Obesity & Metabolism. 2024

Abstract

Efficacy and safety of the insulin glargine plus lixisenatide fixed-ratio combination vs. insulin glargine in patients wth T2DM: the LixiLan-L trial [abstract]. 

Diabetes. 2016

Contact

full name

C. Wysham

Quick Info

 

Collaboration

Co-author network

Map of science